Evidence map›Paper›PMID 40079023›Full record

ArticleBeilstein journal of organic chemistry2025

Cryptophycin unit B analogues.

Thomas Schachtsiek, Jona Voss, Maren Hamsen, Beate Neumann, Hans-Georg Stammler, Norbert Sewald

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Beilstein journal of organic chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thomas Schachtsiek *Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany.
Jona Voss *Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany.ORCID https://orcid.org/0000-0002-4823-8646
Maren HamsenDepartment of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany.
Beate NeumannDepartment of Chemistry, Inorganic and Structural Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany.
Hans-Georg StammlerDepartment of Chemistry, Inorganic and Structural Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany.ORCID https://orcid.org/0000-0002-0918-7057
Norbert SewaldDepartment of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany.ORCID https://orcid.org/0000-0002-0309-2655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug conjugates using toxic payloads are a promising approach for selectively combating cancer while sparing healthy tissue. The lack of highly cytotoxic and at the same time selective therapeutics against cancer is an ongoing challenge. Cryptophycins are a class of cyclic depsipeptides renowned for their high cytotoxicity in the picomolar range often combined with efficacy against multidrug-resistant tumour cell lines. However, cryptophycins failed as stand-alone drugs in cancer treatment, and their naturally occurring derivatives lack a covalent attachment handle. By making use of drug conjugates, toxic payloads such as cryptophycins can be selectively delivered to the target site. We present the synthesis of two conjugable cryptophycins with amino groups in unit B, representing potential payloads for drug conjugates particularly effective against multidrug-resistant cancers.

Indexed as

cancer treatmentcryptophycinsdrug conjugatespayloadtargeted delivery

Identifiers

PMID40079023
PMCPMC11897651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.